WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating
WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating
SHANGHAI, Nov. 20, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been awarded a gold medal in the 2024 EcoVadis business sustainability rating, ranking in the top 2% of all participating companies. This achievement reflects WuXi AppTec's commitment to sustainability and its ongoing efforts to integrate environmental and social responsibilities into the company's business strategies and operations.
上海,2024年11月20日 /PRNewswire/ — 爲製藥和生命科學行業的公司提供廣泛的研發和製造服務的跨國公司藥明康德宣佈在2024年EcoVadis商業可持續發展評級中獲得金牌,在所有參與公司的前2%中名列前2%。這一成就反映了藥明康德對可持續發展的承諾及其將環境和社會責任納入公司業務戰略和運營的持續努力。
EcoVadis is a leading ratings organization in supply chain sustainability, serving as a crucial benchmark for companies of all sizes worldwide to enhance their long-term sustainability performance in business and value chains. WuXi AppTec's EcoVadis score of 80 out of 100 points reflects steady improvements in the four key ESG categories: environment, labor & human rights, ethics, and sustainable procurement.
EcoVadis是供應鏈可持續發展領域的領先評級組織,是全球各種規模的公司提高其在業務和價值鏈中的長期可持續發展表現的重要基準。藥明康德的EcoVadis得分爲80分(滿分100分),這反映了環境、勞動與人權、道德和可持續採購這四個關鍵ESG類別的穩步改善。
"Receiving the EcoVadis Gold Medal is a reflection of the strong progress we have made implementing sustainable development and strong ESG practices throughout our entire value chain," said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec's ESG Committee. "We remain dedicated to advancing sustainability efforts in every aspect of our operations. We are proud to support our customers in delivering innovative new therapies to patients and make a lasting, positive impact on the healthcare industry as a whole."
藥明康德副董事長兼藥明康德ESG委員會主席胡愛德說:「獲得EcoVadis金牌反映了我們在整個價值鏈中實施可持續發展和強有力的ESG實踐所取得的強勁進展。」「我們仍然致力於在運營的各個方面推進可持續發展工作。我們很自豪能夠支持我們的客戶爲患者提供創新的新療法,並對整個醫療保健行業產生持久、積極的影響。」
As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates ESG priorities in all aspects of its global business operations. In 2024, WuXi AppTec ranked #1 in the Global Life Sciences Tools & Services Industry in S&P Global's Corporate Sustainability Assessment and received an AA ESG rating from MSCI for the fourth consecutive year. The company was also named to the S&P Global Sustainability Yearbook and the FTSE4Good Index Series in both 2023 and 2024, and was recognized as an Industry and Regional "Top-Rated" company by Sustainalytics. WuXi AppTec's outstanding ESG performance has been widely acknowledged by major global ESG rating agencies, including CDP and ISS.
作爲創新的推動者、值得信賴的合作伙伴以及全球製藥和生命科學行業的貢獻者,WuXi AppTec將ESG優先事項納入其全球業務運營的各個方面。2024年,藥明康德在標普全球的企業可持續發展評估中在全球生命科學工具和服務行業中排名第 #1 位,並連續第四年獲得摩根士丹利資本國際的AAESG評級。該公司還在2023年和2024年入選標普全球可持續發展年鑑和富時社會責任指數系列,並被Sustainalytics評爲行業和區域 「最受好評」 公司。藥明康德出色的ESG表現得到了包括CDP和ISS在內的全球主要ESG評級機構的廣泛認可。
In addition, WuXi AppTec participates in global efforts to advance sustainability. For example, WuXi AppTec joined the United Nations Global Compact (UNGC) in 2024 to support its ten sustainability principles. In 2023, WuXi AppTec joined the Science Based Targets initiative (SBTi) to reduce carbon emissions.
此外,藥明康德參與全球推動可持續發展的努力。例如,藥明康德於2024年加入聯合國全球契約(UNGC),以支持其十項可持續發展原則。2023年,藥明康德加入了科學目標倡議(SBTi),以減少碳排放。
About WuXi AppTec
關於藥明康德
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
作爲一家在亞洲、歐洲和北美開展業務的跨國公司,藥明康德提供廣泛的研發和製造服務組合,使全球製藥和生命科學行業能夠推進發現併爲患者提供開創性的治療。通過其獨特的商業模式,藥明康德的綜合端到端服務包括化學藥物CRDMO(合同研究、開發和製造組織)、生物學發現、臨床前測試和臨床研究服務、先進療法CTDMO(合同測試、開發和製造組織),通過具有成本效益和高效的解決方案幫助客戶提高推進醫療保健產品的生產力。藥明康德在2024年連續第四年獲得摩根士丹利資本國際公司的AAESG評級,其開放獲取平台使來自30多個國家的6,000多名客戶能夠改善有需要的人的健康狀況,並實現 「每種藥物都可以製造,每種疾病都可以治療」 的願景。
SOURCE WuXi AppTec
來源:無錫AppTec